Hope for Dementia takes the position that it is possible to reduce the number of new diagnoses by finding therapies that eliminate symptoms.  Investing in dementia prevention as a major health policy priority in every country is the first, critical step.   There are currently promising signs of progress in dementia research in the areas of prevention, symptom deceleration and reversal.  Increasing investments in research and services in these areas provides reasonable hope for dementia growth trends to be reduced and ideally, reversed.

Our White Paper proposes a framework to reduce these trends through prevention, deceleration, and reversal of symptoms throughout three levels of public health disease prevention practices and proposes services that should be delivered cost effectively within the health care system.

Tertiary prevention: Improving treatment and recovery / disease reversal

 

Tertiary strategies for dementia involve applying drug therapies proven to drive symptom reversal. Hope for Dementia advocates the proactive recruitment of persons with mild cognitive impairment and diagnosed with early-stage dementia to participate in research and clinical trials on promising symptom reversal.

RESEARCH FINDINGS

  • An article published in the Journal of Biomedical Science in January 2020 indicated that current trends show increased targeting of neuroprotection and anti-neuroinflammation in phase 1 and phase 2 trials, respectively, and a decline in anti-amyloid drug therapy research since 2019.[i]

INSIGHTS

  • There is an increasing shift in pharma research away from amyloid-clearing/cure drug therapies, towards prevention and protection therapies
  • This is greater openness to clinical trials based on alternative hypotheses and therapies on the causes and potential cures for dementia

PREVENTION STRATEGIES

Tertiary prevention: reversal

  • Focus research on symptom reversal as a potential pathway to finding a cure for dementia

SERVICE DELIVERY

Disease protection

  • Establish a dedicated public/private sector fund for promising research and clinical trials on symptom deceleration and reversal therapies
  • Private sector and non-government organizations match the government’s financial allocations in the National Dementia Strategy

To read the complete version of the White Paper, click here.

[i] Journal of Biomedical Science.